We are Changing the Drug Discovery Paradigm
Congruence Therapeutics is a drug discovery company harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning and computational chemistry.
Leadership
We have a uniquely qualified team, founded by serial life sciences entrepreneur Clarissa Desjardins, PhD, most recently the founder and CEO of rare disease company Clementia Pharmaceuticals (Nasdaq: CMTA) sold to Ipsen for US$1.31 billion in 2019. Learn more about our outstanding team below.
In September 2025, Congruence announced the closing of a $32M US financing to advance first-in-class genetic obesity candidate drug CGX-926 through Phase 1b proof of concept clinical trial. The round included participation from all existing investors including: Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capital’s Thrive Venture Fund, OrbiMed, Driehaus, Silver Arc, and Alexandria.
In March 2023, we announced the close of an extension to our Series A financing, bringing the total amount raised to over US$65 million. This extension was led by new investor BDC Capital’s Thrive Venture Fund, with participation from current investors Amplitude Ventures, Fonds de solidarité FTQ, OrbiMed, Investissement Quebec (IQ), SilverArc, and others.
In December 2021, we completed a Series A financing of US$50 million with top U.S. and Canadian investors, including OrbiMed, Amplitude Ventures, and Driehaus.
